Intellia moves closer to clinic with CRISPR tech – FierceBiotech
Korea JoongAng Daily |
Intellia moves closer to clinic with CRISPR tech
FierceBiotech Intellia Therapeutics has taken another step toward human trials of its gene editing technology, after reporting new data in animal models. The CRISPR specialist says it has been able to show for the first time that it is able to not only achieve long … Crispr Therapeutics AG (CRSP) Given $25.83 Average Target Price by Brokerages ToolGen, Inc. Announces Poster Presentation on Genome Editing of Human T Cells at 2017 American Society for Gene … [Korea and the fourth industrial revolution] When the cure is slicing DNA, printing organs |
